To Revolutionize Antibiotic Pipeline Start With Rapid Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Point-of-care diagnostics can make antibiotic development faster, easier and cheaper, but creating them will be a bumpy ride, according to a recent discussion among government and industry officials.
You may also be interested in...
Antibiotics Legislation Could Boost Confidence Of Sponsors And FDA Alike
A limited population antibacterial drug pathway could reassure investors about the viability of antibiotics and help FDA avoid looking over its shoulder as it approves products based on limited data, though enactment is uncertain.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.